Aranesp Declines Put More Pressure On Amgen For Denosumab Success

With sales of Amgen's blockbuster anemia franchise in a freefall and competitive threats to its tumor necrosis factor inhibitor Enbrel looming, the big biotech is banking on the osteoporosis treatment denosumab to drive growth in the years ahead

More from Archive

More from Pink Sheet